Cite as: 562 U. S. ____ (2011)

1

Opinion of the Court
NOTICE: This opinion is subject to formal revision before publication in the
preliminary print of the United States Reports. Readers are requested to
notify the Reporter of Decisions, Supreme Court of the United States, Wash
ington, D. C. 20543, of any typographical or other formal errors, in order
that corrections may be made before the preliminary print goes to press.

SUPREME COURT OF THE UNITED STATES
_________________

No. 09–152
_________________

RUSSELL BRUESEWITZ, ET AL., PETITIONERS v. 

WYETH LLC, FKA WYETH, INC., FKA WYETH

LABORATORIES, ET AL. 

ON WRIT OF CERTIORARI TO THE UNITED STATES COURT OF

APPEALS FOR THE THIRD CIRCUIT

[February 22, 2011] 


JUSTICE SCALIA delivered the opinion of the Court.
We consider whether a preemption provision enacted in
the National Childhood Vaccine Injury Act of 1986
(NCVIA)1 bars state-law design-defect claims against
vaccine manufacturers.
I

A

For the last 66 years, vaccines have been subject to the
same federal premarket approval process as prescription
drugs, and compensation for vaccine-related injuries has
been left largely to the States.2 Under that regime, the
elimination of communicable diseases through vaccination
became “one of the greatest achievements” of public health
in the 20th century.3 But in the 1970’s and 1980’s vac
——————
1 42

U. S. C. §300aa–22(b)(1).
P. Hutt, R. Merrill, & L. Grossman, Food and Drug Law 912–
913, 1458 (3d ed. 2007).
3 Centers for Disease Control, Achievements in Public Health, 1900–
1999: Impact of Vaccines Universally Recommended for Children, 48
Morbidity and Mortality Weekly Report 243, 247 (Apr. 2, 1999).
2 See

